Research and Reviews: Drug Delivery

Advanced Drug Delivery Strategies for Targeting Cancer Cells

Emily Cooper*

Department of Pharmacy, Aix-Marseille University, Marseille, France

Opinion Article

Received: 01-Mar-2023, Manuscript No. DD-23-94109; **Editor assigned:** 03-Mar-2023, PreQC No. DD-23-94109 (PQ); **Reviewed:** 17-Mar-2023, QC No DD-23-94109; **Revised:** 24-Mar-2023, Manuscript No. DD23- 94109 (R); **Published:** 31-Mar-2023, DOI: 10.4172/resrevdrugdeliv.7.1.006

***For Correspondence:**
Emily Cooper, Department of Pharmacy, Aix-Marseille University, Marseille, France
E-mail: cooperemi090@gmail.com

Citation: Cooper E. Advanced Drug Delivery Strategies for Targeting Cancer Cells. Res Rev Drug Deliv.2023;11:006.

DESCRIPTION

Cancer is one of the most common and lethal diseases in the world. Despite the tremendous progress made in the field of cancer treatment, the current therapies are still associated with several limitations, including toxicity, lack of selectivity and drug resistance. Therefore, there is a critical need to develop new and innovative drug delivery strategies that can overcome these limitations and improve the efficacy of cancer treatment. Over the past few decades, significant advancements have been made in the field of drug delivery, leading to the development of several novel strategies for targeting cancer cells. In this article, we will discuss some of the most promising drug delivery strategies that are currently being investigated for the treatment of cancer.

Nanoparticle based drug delivery systems

Nanoparticle-based drug delivery systems have emerged as a promising strategy for targeting cancer cells. These systems are typically composed of biocompatible and biodegradable materials, such as lipids, polymers or metals, and can be designed to selectively accumulate in tumor tissues through the enhanced permeability and retention effect. Nanoparticle-based drug delivery systems offer several advantages over conventional chemotherapy, including improved drug solubility, prolonged circulation time and enhanced tumor penetration. Additionally, nanoparticles can be functionalized with targeting moieties, such as antibodies or peptides that can specifically bind to cancer cells and improve the selectivity of drug delivery.

Antibody drug conjugates

Antibody-Drug Conjugates (ADCs) are a class of targeted drug delivery systems that combine the specificity of antibodies with the cytotoxicity of small molecule drugs. These systems consist of an antibody that is conjugated to a cytotoxic drug through a linker molecule. The antibody component of ADCs binds to a specific antigen that is overexpressed on the surface of cancer cells, leading to the internalization and intracellular release of the cytotoxic drug. ADCs offer several advantages over conventional chemotherapy, including improved efficacy, decreased toxicity and enhanced selectivity.

Stimuli responsive drug delivery systems

Stimuli-responsive drug delivery systems are designed to release drugs in response to specific stimuli, such as changes in pH, temperature or enzyme activity. These systems can be engineered to selectively release drugs in the tumor microenvironment, leading to improved efficacy and reduced toxicity. One example of a stimuli-responsive drug delivery system is pH-responsive nanoparticles, which can release drugs in response to the acidic environment of tumor tissues. Another example is enzyme-responsive hydrogels, which can release drugs in response to the activity of enzymes that are overexpressed in cancer cells.

Cell based drug delivery systems

Cell-based drug delivery systems involve the use of cells as carriers for therapeutic agents. These systems can be engineered to selectively target cancer cells and deliver therapeutic agents directly to the site of the tumor. One example of a cell-based drug delivery system is Mesenchymal Stem Cells (MSCs), which have been shown to selectively accumulate in tumor tissues and deliver therapeutic agents to cancer cells. MSCs can be engineered to express specific proteins or peptides that can enhance their targeting ability and improve the efficacy of drug delivery. Advanced drug delivery strategies have the potential to revolutionize the field of cancer treatment by overcoming the limitations of conventional chemotherapy and improving the efficacy of cancer therapy. Nanoparticle-based drug delivery systems, antibody-drug conjugates, stimuli-responsive drug delivery systems and cell-based drug delivery systems are some of the most promising strategies that are currently being investigated for the treatment of cancer. Although these strategies are still in the early stages of development, they hold great promise for the future of cancer treatment. It is hoped that these advanced drug delivery strategies will pave the way for the development of more effective and targeted therapies for cancer patients.